{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:31:50Z","timestamp":1791433910699,"version":"4.3.3"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008090","name":"Tufts University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"US Government National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clinthera.2025.12.014","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:30:24Z","timestamp":1768998624000},"page":"196-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Time Trends in Prescribing of Anxiolytic, Sedative, and Hypnotic Drugs in the United States"],"prefix":"10.1016","volume":"48","author":[{"given":"Zhengzhe","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard I.","family":"Shader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Greenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.12.014_bib0001","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.1970.03170350023005","article-title":"Comprehensive drug surveillance","volume":"213","author":"Jick","year":"1970","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0002","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archpsyc.1975.01760220130014","article-title":"Psychotropic drug use in the Boston area. A report from the Boston collaborative drug surveillance program","volume":"32","author":"Greenblatt","year":"1975","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JCP.0b013e318209cf05","article-title":"Psychotropic drug prescribing in the United States: extent, costs, and expenditures","volume":"31","author":"Greenblatt","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JCP.0000000000000831","article-title":"Update on psychotropic drug prescribing in the United States: 2014-2015","volume":"38","author":"Greenblatt","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0005","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199305133281907","article-title":"Use of benzodiazepines in anxiety disorders","volume":"328","author":"Shader","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0006","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s13311-012-0148-3","article-title":"Insomnia pharmacotherapy","volume":"9","author":"Roehrs","year":"2012","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0007","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1517\/14656566.2012.667074","article-title":"Zolpidem for insomnia","volume":"13","author":"Greenblatt","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0008","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1517\/17425255.2012.741588","article-title":"Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications","volume":"8","author":"Greenblatt","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0009","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","article-title":"Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders","volume":"16","author":"Muehlan","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2165\/00023210-199707010-00007","article-title":"Buspirone: an updated review of its clinical pharmacology and therapeutic applications","volume":"7","author":"Fulton","year":"1997","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brainres.2012.04.032","article-title":"Buspirone: what is it all about?","volume":"1461","author":"Loane","year":"2013","journal-title":"Brain Res"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0012","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1001\/jama.2020.19224","article-title":"Trends in dispensing of zolpidem and low-dose trazodone among commercially insured adults in the United States, 2011-2018","volume":"324","author":"Wong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0013","first-page":"qxaf114","article-title":"Off-label policy through the lens of trazodone usage and spending in the United States","volume":"3","author":"Kadiyala","year":"2025","journal-title":"Health Aff Sch"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0014","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1517\/14656566.2012.699523","article-title":"Off-label uses of trazodone: a review","volume":"13","author":"Bossini","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5665\/sleep.3410","article-title":"National use of prescription medications for insomnia: NHANES 1999-2010","volume":"37","author":"Bertisch","year":"2014","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0016","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.2105\/AJPH.2016.303382","article-title":"Continuing versus new prescriptions for sedative-hypnotic medications: United States, 2005-2012","volume":"106","author":"Kaufmann","year":"2016","journal-title":"Am J Public Health"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/j.1875-9114.1981.tb03546.x","article-title":"Evaluation of temazepam as a hypnotic","volume":"1","author":"Mitler","year":"1981","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0018","first-page":"229","article-title":"The benzodiazepine story","volume":"22","author":"Sternbach","year":"1978","journal-title":"Prog Drug Res"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0019","series-title":"Benzodiazepines in Clinical Practice","author":"Greenblatt","year":"1974"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107310","article-title":"Leo Sternbach and the benzodiazepines 60 years on: a revolutionary treatment for anxiety disorders","volume":"207","author":"Junkes","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0021","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.janxdis.2011.01.002","article-title":"The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: half a century of anxiolytic drugs","volume":"25","author":"L\u00f3pez-Mu\u00f1oz","year":"2011","journal-title":"J Anxiety Disord"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2024.173858","article-title":"Anxiolytics: origins, drug discovery, and mechanisms","volume":"245","author":"Witkin","year":"2024","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0023","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4140\/TCP.n.2013.538","article-title":"The history of benzodiazepines","volume":"28","author":"Wick","year":"2013","journal-title":"Consult Pharm"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0024","doi-asserted-by":"crossref","unstructured":"Greenblatt D.J. Shader R.I. Benzodiazepines. N Engl J Med. 1974; 291: 1011-1015 and 1239\u20131243. doi:10.1056\/NEJM197411072911906.","DOI":"10.1056\/NEJM197412052912308"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0025","doi-asserted-by":"crossref","unstructured":"Greenblatt D.J., Shader R.I., Abernethy DR. Current status of benzodiazepines. N Engl J Med. 1983; 309: 354-358 and 410-416. doi:10.1056\/NEJM198308113090607.","DOI":"10.1056\/NEJM198308183090705"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0026","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/cpt1977214497","article-title":"Acute overdosage with benzodiazepine derivatives","volume":"21","author":"Greenblatt","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0027","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00426470","article-title":"Benzodiazepine overdosage: plasma concentrations and clinical outcome","volume":"73","author":"Divoll","year":"1981","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0028","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/03602537808993775","article-title":"Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations","volume":"8","author":"Greenblatt","year":"1978","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0029","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/03602538308991391","article-title":"Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics","volume":"14","author":"Greenblatt","year":"1983","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0030","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/pds.3951","article-title":"Trends in prescribing of sedative-hypnotic medications in the USA: 1993-2010","volume":"25","author":"Kaufmann","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7399","article-title":"Patterns in outpatient benzodiazepine prescribing in the United States","volume":"2","author":"Agarwal","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0032","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.5664\/jcsm.10132","article-title":"Declining trend in use of medications for sleep disturbance in the United States from 2013 to 2018","volume":"18","author":"Kaufmann","year":"2022","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0033","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/00912174231166252","article-title":"Chronic use of benzodiazepines: the problem that persists","volume":"58","author":"Louie","year":"2023","journal-title":"Int J Psychiatry Med"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0034","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1176\/appi.ajp.20240030","article-title":"Setting the record straight on long-term use, dose escalation, and potential misuse of prescription benzodiazepines","volume":"181","author":"Soumerai","year":"2024","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0035","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1176\/appi.ajp.20230075","article-title":"Long-term use of benzodiazepines and benzodiazepine-related drugs: a register-based Danish cohort study on determinants and risk of dose escalation","volume":"181","author":"Rosenqvist","year":"2024","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0036","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23com14959","article-title":"Resolving the paradox of long-term benzodiazepine treatment: toward evidence-based practice guidelines","volume":"84","author":"Silberman","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0037","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000546269","article-title":"Comparative efficacy and safety of benzodiazepines in the treatment of patients with generalized anxiety disorder: a systematic review and network meta-analysis","volume":"94","author":"Fernandes","year":"2025","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0038","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000489538","article-title":"International task force on benzodiazepines","volume":"87","author":"Balon","year":"2018","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0039","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/JCP.0000000000000383","article-title":"Not again: benzodiazepines once more under attack","volume":"35","author":"Salzman","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1192\/bjp.2020.164","article-title":"Benzodiazepines: it\u2019s time to return to the evidence","volume":"218","author":"Silberman","year":"2021","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0041","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000525208","article-title":"Stigmatization of benzodiazepines: pharmacologic and nonpharmacologic contributions","volume":"91","author":"Silberman","year":"2022","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0042","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1590\/1516-4446-2019-0773","article-title":"The rise and fall and rise of benzodiazepines: a return of the stigmatized and repressed","volume":"42","author":"Balon","year":"2020","journal-title":"Braz J Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0043","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/JCP.0000000000000908","article-title":"The prescription of benzodiazepines for panic disorder: time for an evidence-based educational approach","volume":"38","author":"Nardi","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0044","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000524400","article-title":"Benzodiazepines remain important therapeutic options in psychiatric practice","volume":"91","author":"Dubovsky","year":"2022","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0045","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","article-title":"Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review","volume":"19","author":"Gomez","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0046","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1517\/14656566.2015.1059424","article-title":"Pharmacological treatment for generalized anxiety disorder in adults: an update","volume":"16","author":"Reinhold","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.comppsych.2024.152479","article-title":"Meta-analysis of the comparative efficacy of benzodiazepines and antidepressants for psychic versus somatic symptoms of generalized anxiety disorder","volume":"132","author":"Beyer","year":"2024","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0048","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/15622975.2018.1500031","article-title":"Benzodiazepines in anxiety disorders: reassessment of usefulness and safety","volume":"20","author":"Rickels","year":"2019","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0049","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.595584","article-title":"Pharmacotherapy of anxiety disorders: current and emerging treatment options","volume":"11","author":"Garakani","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0050","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4088\/JCP.v66n0409","article-title":"A review of the evidence for the efficacy and safety of trazodone in insomnia","volume":"66","author":"Mendelson","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0051","doi-asserted-by":"crossref","first-page":"752","DOI":"10.4088\/JCP.v65n0605","article-title":"The use of trazodone as a hypnotic: a critical review","volume":"65","author":"James","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0052","first-page":"24","article-title":"Trazodone for insomnia: a systematic review","volume":"14","author":"Jaffer","year":"2017","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0053","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.sleep.2018.01.010","article-title":"Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials","volume":"45","author":"Yi","year":"2018","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0054","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.3390\/jcm12082933","article-title":"Should trazodone be first-line therapy for insomnia? A clinical suitability appraisal","volume":"12","author":"Pelayo","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0055","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40263-024-01110-2","article-title":"Effects of trazodone on sleep: a systematic review and meta-analysis","volume":"38","author":"Kokkali","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0056","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14088","article-title":"Comparative short-term safety and efficacy of hypnotics: a quantitative risk-benefit analysis","volume":"33","author":"Cheung","year":"2024","journal-title":"J Sleep Res"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0057","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smrv.2012.08.001","article-title":"Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications","volume":"17","author":"Krystal","year":"2013","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0058","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1176\/appi.ajp.2020.20040376","article-title":"Benzodiazepines: a perspective","volume":"177","author":"Rosenbaum","year":"2020","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0059","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.2020.22106","article-title":"Balancing the risks and benefits of benzodiazepines","volume":"325","author":"Hirschtritt","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2025.12.014_bib0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1176\/appi.ps.202100671","article-title":"Walking the benzodiazepine high wire","volume":"74","author":"Kroenke","year":"2023","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.clinthera.2025.12.014_bib61","article-title":"Benefits and Liabilities of Benzodiazepines and Z-Drugs: What We Know and What We Don\u2019t Know","author":"Silberman","year":"2025","journal-title":"Drugs"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825004242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825004242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:33:05Z","timestamp":1773988385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825004242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0149291825004242"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.12.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time Trends in Prescribing of Anxiolytic, Sedative, and Hypnotic Drugs in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}